The manufacturer of Auvelity is Axsome Therapeutics [1].
Who else is involved with Auvelity?
While Axsome Therapeutics is the manufacturer, Grünenthal is the company responsible for the commercialization of Auvelity in Europe [2].
What is Auvelity used for?
Auvelity is a medication used for the treatment of major depressive disorder (MDD) in adults [1].
How does Auvelity work?
Auvelity contains two active ingredients: dextromethorphan and bupropion [1]. Dextromethorphan is believed to act as an N-methyl-D-aspartate (NMDA) receptor antagonist [3]. Bupropion is believed to inhibit the reuptake of norepinephrine and dopamine [3]. The combination of these mechanisms is thought to modulate glutamatergic and dopaminergic neurotransmission, which are implicated in MDD [3].
When did Auvelity become available?
Auvelity received FDA approval in August 2022 [1].
What are the potential side effects of Auvelity?
Common side effects of Auvelity include dizziness, nausea, constipation, insomnia, and dry mouth [1]. More serious risks can involve suicidal thoughts and behaviors, and the potential for seizures [1]. Patients taking Auvelity should be monitored for these risks [1].
Are there any drug interactions with Auvelity?
Yes, Auvelity has significant drug interactions. It should not be taken with monoamine oxidase inhibitors (MAOIs) [1]. Bupropion, one of the active ingredients, can also increase the risk of seizures, and this risk is amplified when taken with other medications that lower the seizure threshold [1]. Additionally, Auvelity can affect the metabolism of other drugs, leading to potentially dangerous levels of those medications in the body [1].